Combined Physical-cognitive Exercise and Dietary Intervention for Postmenopausal Obese Women
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04768725 |
|
Recruitment Status :
Recruiting
First Posted : February 24, 2021
Last Update Posted : February 25, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Obesity | Behavioral: Dietary intervention combined with physical-cognitive exergaming Behavioral: Dietary intervention Behavioral: Physical-cognitive intervention | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 92 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Other |
| Official Title: | A Randomized Controlled Trial Investigating the Effects of Combined Physical-cognitive Exercise and Dietary Intervention on Cognitive Performance and Changes in Blood Biomarkers of Postmenopausal Obese Women |
| Actual Study Start Date : | September 26, 2021 |
| Estimated Primary Completion Date : | December 2022 |
| Estimated Study Completion Date : | May 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Dietary intervention
Participants will consume a self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day).
|
Behavioral: Dietary intervention
Intermittent Fasting (IF) [self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)]. |
|
Active Comparator: Physical-cognitive intervention
Participants will perform home-based physical-cognitive training for 60 minutes per session, 3 session a week.
|
Behavioral: Physical-cognitive intervention
Physical-cognitive exercise [60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)]. |
|
Experimental: Physical-cognitive with dietary intervention
Participants will receive both dietary intervention and physical-cognitive training same as those in the dietary and physical-cognitive intervention groups.
|
Behavioral: Dietary intervention combined with physical-cognitive exergaming
Intermittent Fasting (IF) [self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)] combined with physical-cognitive exercise [60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)]. |
|
No Intervention: Control
Participants in the control group will be encouraged to continue their activities and calorie intakes as they usually would.
|
- change from baseline time to complete Trail Making B-A at 12 weeks [ Time Frame: 12 weeks ]Time to complete Trail Making B and A will be recorded in seconds. The difference between time to complete Trail B and A will be used to index the task switching ability, a subdomain of executive function. Smaller differences between B-A indicate better switching ability.
- change from baseline Stroop Color and Word score at 12 weeks [ Time Frame: 12 weeks ]In Stroop Color and Word test, the number of items correctly identified in 45 seconds in each condition (i.e. word, color, color-word) will be recorded. Then the predicted score will be calculated. Score will be obtained from the different between the color-word and predicted scores. Lower scores indicate greater difficulty in inhibiting interference.
- change from baseline Logical Memory score at 12 weeks [ Time Frame: 12 weeks ]In Logical Memory test, participants will be instructed to listen carefully to two stories and remember their contents. After a 30-delay, they will be asked to freely recall the passages (recall) and respond yes or no to the given questions (recognition). The possible scores are 0-75. Higher scores indicate better episodic memory.
- change from baseline Brain-derived neurotrophic factor (BDNF) level at 12 weeks [ Time Frame: 12 weeks ]Level of plasma BDNF will be determined before and after the intervention.
- change from baseline Montreal Cognitive Assessment (MoCA) score at 12 weeks [ Time Frame: 12 weeks ]The Montreal Cognitive Assessment will be used to index global cognitive function. The possible scores are 0-30. Higher scores indicate better cognitive function.
- change from baseline Verbal Fluency score at 12 weeks [ Time Frame: 12 weeks ]Category fluency subtest (naming test) of Verbal Fluency will be used. Participants will be asked to produce as many words as possible in 60 seconds. Higher scores indicate better language ability.
- change from baseline Digit Span score at 12 weeks [ Time Frame: 12 weeks ]In Digit Span test, lists of numbers will be presented orally to participants. They are asked to repeat the numbers immediately in ascending (forward) or reverse (backward) numerical order. The possible scores are 0-28. Higher scores indicate better attention.
- change from baseline plasma adiponectin levels at 12 weeks [ Time Frame: 12 weeks ]Level of plasma adiponectin will be determined before and after intervention.
- change from baseline plasma Interleukin 6 (IL-6) levels at 12 weeks [ Time Frame: 12 weeks ]Level of plasma IL-6 will be determined before and after intervention.
- change from baseline insulin resistance levels at 12 weeks [ Time Frame: 12 weeks ]Level of insulin resistance will be assessed using the homeostasis model assessment (HOMA-IR) index [fasting glucose (mg/dL) X fasting insulin (µU/mL) / 405].
- change from baseline Six-minute walk distance at 12 weeks [ Time Frame: 12 weeks ]The distance (in meters) participants walked in 6 minutes will be determined. Longer distance indicates better cardiorespiratory fitness.
- change from baseline 30 seconds Chair Stand Test at 12 weeks [ Time Frame: 12 weeks ]The number of repetitions participants could perform sit-to-stand will be recorded. Higher number of repetitions indicates greater lower-body strength.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 45 Years to 59 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- obese women (body mass index (BMI) ≥ 25 kg/m2 with waist-to-hip ratio (WHR) ≥ 0.80)
- post-menopausal (self-reported menstrual characteristics (last menstruation > 1 year) or confirmed by blood follicular stimulating hormone (FSH) level ( > 20 IU/L) and estradiol level ( ≤ 30 pg/ml))
- sedentary lifestyle (exercise < 1 hr./wk.)
- normal range of the Mental State Examination T10 (MSET10) score
- at least 6 years of education
- own a mobile phone that supports application platform
- able to comply with the study schedule and procedures
Exclusion Criteria:
- have medical conditions that would be unsafe to exercise or have been diagnosed with neurological conditions (e.g. Parkinson's disease, stroke, multiple sclerosis) that affect cognition and mobility
- have weight variation ( > 5 kilogram in 3 months)
- have other dietary restrictions (e.g. vegetarianism and veganism)
- have depressive symptoms defined as a score ≥ 11 on Hospital Anxiety Depression Scale (HADS)
- have an uncorrected visual or hearing impairment
- receive hormonal replacement therapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04768725
| Contact: Somporn Sungkarat, PhD | 6653949249 | somporn.sungkarat@cmu.ac.th |
| Thailand | |
| Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University | Recruiting |
| Chiang Mai, Thailand, 50200 | |
| Contact: Somporn Sungkarat, PhD +6653-94-9249 somporn.sungkarat@cmu.ac.th | |
| Principal Investigator: Somporn Sungkarat, PhD | |
| Principal Investigator: | Somporn Sungkarat, PhD | Chiang Mai University |
| Responsible Party: | Somporn Sungkarat, Associate Professor, Chiang Mai University |
| ClinicalTrials.gov Identifier: | NCT04768725 |
| Other Study ID Numbers: |
AMS-PT CMU 2564 |
| First Posted: | February 24, 2021 Key Record Dates |
| Last Update Posted: | February 25, 2022 |
| Last Verified: | February 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Dietary intervention Cognitive function Brain-derived neurotrophic factor Exergaming Obesity |
|
Obesity Overnutrition Nutrition Disorders Overweight Body Weight |

